Skip to main content

Advertisement

Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib

Fig. 6

Evaluation of in vivo anti-tumor efficacy in the xenograft nude mouse model. a The tumor volumes were recorded every other day from the start of treatment until the end point. Photographs (b) and tumor weights (c) of the excised tumors from each group at the end point. Data are expressed as the mean ± SD (n = 5). Compared with the control group, *P < 0.05, **P < 0.01, ***P < 0.001; Compared with the LFC-Sora/Meta-NPs group, #P < 0.05, ##P < 0.01, ###P < 0.001

Back to article page